Compare CELU & CXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CELU | CXH |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 65.6M |
| IPO Year | N/A | N/A |
| Metric | CELU | CXH |
|---|---|---|
| Price | $1.83 | $7.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 62.1K | 25.9K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | ★ $40,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | ★ N/A | $33.35 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $6.41 |
| 52 Week High | $4.35 | $7.74 |
| Indicator | CELU | CXH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.51 |
| Support Level | N/A | $7.91 |
| Resistance Level | N/A | $8.00 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 30.00 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.